Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Corindus Vascular Robotics, Inc. (NYSE: CVRS) on Behalf of Corindus Shareholders and Encourages Corindus Investors to Contact the Firm


NEW YORK, Aug. 8, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Corindus Vascular Robotics, Inc. (NYSE: CVRS) on behalf of Corindus shareholders concerning the proposed merger with a subsidiary of Siemens Healthineers AG.

(PRNewsfoto/Bragar Eagel & Squire, P.C.)

Click here to participate in the action.

Pursuant to the proposed transaction, announced on August 8, 2019 and valued at $1.1 billion, Corindus shareholders will receive $4.28 in cash for each share of Corindus common stock owned.  The investigation focuses on whether Corindus and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company's shareholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.

If you own Corindus shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at, or telephone at (212) 308-1869, or by filling out this contact form.  There is no cost or obligation to you.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation.  For additional information concerning our investigation of Corindus please go to  For additional information about Bragar Eagel & Squire, P.C. please go to  Attorney advertising.  Prior results do not guarantee similar outcomes. 


Cision View original content to download multimedia:

SOURCE Bragar Eagel & Squire, P.C.

Company Codes: AMEX:CVRS

Back to news